Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 41 - 60 ( 441 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Partnership Termination; Multiple Programs Halted; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading FATE to NEUTRAL FATE Gets Divorced, Downsizes the House
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASH Day 3 Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Here we summarize the presentations relevant to FATE, including interim Ph 1 data from FT819 in r/r BCL,
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC Takeaways; All Eyes on ASH Now; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2022 Conference Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department